Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

NCT00044044
completedphase_2

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005
withdrawnphase_3

Major Depressive Disorder With Mixed Features

NCT01423240

Clinical Trials (3)

Showing 3 of 3 trials
NCT00044044Phase 2

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Completed
NCT00044005Phase 2

Safety and Tolerability Study of Drug to Treat Schizophrenia

Completed
NCT01423240Phase 3

Major Depressive Disorder With Mixed Features

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3